

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: La Fleur et al.

Application Number: Not assigned

Group Art Unit: Not assigned

Filed: Concurrently herewith

Examiner: Not assigned

Title: **44 Human Secreted Proteins**

Attorney Docket No. PZ024P1C1

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to examining the captioned application, Applicants respectfully request entry of the following amendments.

**In the Specification:**

**At Page 1, immediately following the title, but before "*Field of the Invention*," please insert the following paragraph:**

This Application is a continuation of, and claims priority under 35 U.S.C. § 120 to, U.S. Application 09/369,247 (filed on August 5, 1999), which is a continuation-in-part of, and claims priority under 35 U.S.C. § 120 to, international application PCT/US/99/02293 (filed on February 4, 1999), which is a non-provisional of, and claims benefit under 35 U.S.C. § 119(e) to, U.S. Provisional Applications 60/074,118; 60/074,157; 60/074,037; 60/074,141; and, 60/074,341 (each filed on February 9, 1998). Each of the above referenced applications is hereby incorporated by reference in its entirety herein.

**At page 91, above line 1, please insert the following header:**

**Table 1**

**In the Claims:**

**Please replace claim 17 with the following amended claim:**

17. (Once Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.


***Remarks***

Applicants have amended the specification to include information regarding applications to which the present application claims priority. Applicants have also amended the specification to include a header for Table 1 immediately prior to the first occurrence of Table 1. Table 1, and the data therein, are fully described in the specification as originally filed (see, for example, pages 96-97). Original claim 17 has been amended to eliminate a multiple dependency. No new matter has been added by the present amendments.

Applicants respectfully request that the amendments and remarks of the present response be entered and made of record in the present application. If a fee is required in connection with this paper, please charge Deposit Account No. 08-3425 for the appropriate amount.

Respectfully submitted

Date: February 5, 2002



Janet M. Martineau (Reg. No. 46,903)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 315-2723 (telephone)

JMM/DAS/rmr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: La Fleur et al.

Application Number: Not assigned

Group Art Unit: Not assigned

Filed: Concurrently herewith

Examiner: Not assigned

Title: 44 Human Secreted Proteins

Attorney Docket No. PZ024P1C1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

At Page 1, immediately following the title, but before "*Field of the Invention*," the following paragraph has been inserted:

This Application is a continuation of, and claims priority under 35 U.S.C. § 120 to, U.S. Application 09/369,247 (filed on August 5, 1999), which is a continuation-in-part of, and claims priority under 35 U.S.C. § 120 to, international application PCT/US/99/02293 (filed on February 4, 1999), which is a non-provisional of, and claims benefit under 35 U.S.C. § 119(e) to, U.S. Provisional Applications 60/074,118; 60/074,157; 60/074,037; 60/074,141; and, 60/074,341 (each filed on February 9, 1998). Each of the above referenced applications is hereby incorporated by reference in its entirety herein.

At page 91, above line 1, please insert the following header:

Table 1

Claim 17 has been amended as follows:

17. (Once Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 ~~or the polynucleotide of claim 1.~~